Paclitaxel as a radiosensitizer combined with fractionated stereotactic radiotherapy in the treatment of recurrent medulloblastoma

Dave E. Gannett, Donald Hill, Allan J Hamilton, Baldassarre Stea

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

This report describes the treatment of a 39-year-old man with recurrent medulloblastoma previously treated with extensive chemotherapy and radiation therapy. A novel treatment technique combining paclitaxel (275 mg IV bolus) and fractionated stereotactic radiotherapy (30 Gy in six fractions over 3 weeks) was given to palliate the patient's significant neurologic symptoms. The patient experienced a significant improvement both radiographically and in the quality of his life at follow-up 5 months after completion of treatment. No toxicity has been observed. The treatment of medulloblastoma with paclitaxel and fractionated stereotactic radiotherapy, either alone or in combination, merits further investigation.

Original languageEnglish (US)
Pages (from-to)233-236
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume20
Issue number3
DOIs
StatePublished - Jun 1997

Fingerprint

Medulloblastoma
Paclitaxel
Radiotherapy
Therapeutics
Neurologic Manifestations
Quality of Life
Drug Therapy

Keywords

  • Medulloblastoma
  • Paclitaxel
  • Radiation Sensitizer
  • Stereotactic radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{646988abd01f4bab99ebccbd3f182cb2,
title = "Paclitaxel as a radiosensitizer combined with fractionated stereotactic radiotherapy in the treatment of recurrent medulloblastoma",
abstract = "This report describes the treatment of a 39-year-old man with recurrent medulloblastoma previously treated with extensive chemotherapy and radiation therapy. A novel treatment technique combining paclitaxel (275 mg IV bolus) and fractionated stereotactic radiotherapy (30 Gy in six fractions over 3 weeks) was given to palliate the patient's significant neurologic symptoms. The patient experienced a significant improvement both radiographically and in the quality of his life at follow-up 5 months after completion of treatment. No toxicity has been observed. The treatment of medulloblastoma with paclitaxel and fractionated stereotactic radiotherapy, either alone or in combination, merits further investigation.",
keywords = "Medulloblastoma, Paclitaxel, Radiation Sensitizer, Stereotactic radiotherapy",
author = "Gannett, {Dave E.} and Donald Hill and Hamilton, {Allan J} and Baldassarre Stea",
year = "1997",
month = "6",
doi = "10.1097/00000421-199706000-00004",
language = "English (US)",
volume = "20",
pages = "233--236",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Paclitaxel as a radiosensitizer combined with fractionated stereotactic radiotherapy in the treatment of recurrent medulloblastoma

AU - Gannett, Dave E.

AU - Hill, Donald

AU - Hamilton, Allan J

AU - Stea, Baldassarre

PY - 1997/6

Y1 - 1997/6

N2 - This report describes the treatment of a 39-year-old man with recurrent medulloblastoma previously treated with extensive chemotherapy and radiation therapy. A novel treatment technique combining paclitaxel (275 mg IV bolus) and fractionated stereotactic radiotherapy (30 Gy in six fractions over 3 weeks) was given to palliate the patient's significant neurologic symptoms. The patient experienced a significant improvement both radiographically and in the quality of his life at follow-up 5 months after completion of treatment. No toxicity has been observed. The treatment of medulloblastoma with paclitaxel and fractionated stereotactic radiotherapy, either alone or in combination, merits further investigation.

AB - This report describes the treatment of a 39-year-old man with recurrent medulloblastoma previously treated with extensive chemotherapy and radiation therapy. A novel treatment technique combining paclitaxel (275 mg IV bolus) and fractionated stereotactic radiotherapy (30 Gy in six fractions over 3 weeks) was given to palliate the patient's significant neurologic symptoms. The patient experienced a significant improvement both radiographically and in the quality of his life at follow-up 5 months after completion of treatment. No toxicity has been observed. The treatment of medulloblastoma with paclitaxel and fractionated stereotactic radiotherapy, either alone or in combination, merits further investigation.

KW - Medulloblastoma

KW - Paclitaxel

KW - Radiation Sensitizer

KW - Stereotactic radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0030941838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030941838&partnerID=8YFLogxK

U2 - 10.1097/00000421-199706000-00004

DO - 10.1097/00000421-199706000-00004

M3 - Article

C2 - 9167743

AN - SCOPUS:0030941838

VL - 20

SP - 233

EP - 236

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -